Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Inclusion Criteria: * Age ≥ 18 and ≤ 80 years old at screening. * Presence of ≥ 7.5% steatosis on screening MRI-PDFF read centrally by a radiologist and performed either during the screening period or within 6 months prior to the first visit. * HbA1c ≤ 9.5%. * Normal or minimally abnormal renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73 m\^2 Exclusion Criteria: * Presence or history of cirrhosis or evidence of decompensated liver disease (e.g., ascites, variceal bleeding) or hepatocellular carcinoma. * History or presence of other concomitant liver disease as assessed by the investigator or determined by laboratory findings. * Uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c of \> 9.5% within 60 days prior to enrollment. * Change in anti-diabetic therapy within 6 months prior to qualifying liver biopsy.